Customizing the management of chronic hepatitis B virus infection

Seminars in Liver Disease

Volumn 27, Issue SUPPL. 1, 2007, Pages 9-17

  Gish, Robert G ^a   Perrillo, Robert P ^b   Jacobson, Ira M ^c  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antiviral resistance; Antiviral therapy; HBV DNA; Hepatitis B; Interferon; Nucleoside and nucleotide inhibitors

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RNA DIRECTED DNA POLYMERASE; TELBIVUDINE; TENOFOVIR;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG APPROVAL; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT PLANNING; UNITED STATES; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LAMIVUDINE; MALE; MIDDLE AGED; NUCLEOSIDES; NUCLEOTIDES;

EID: 34548136060     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984695     Document Type: Conference Paper

References (57)

1. World Heath Organization. Hepatitis B 2000. Available at: http://www.who.int/mediacentre/factsheets/fs204/en. Accessed June 6, 2006
2. Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-1956
3. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305
4. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004;2:266-272
5. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-1425
6. Gish RG, Trinh H, Leung N, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study. J Hepatol 2005;43:60-66
7. Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B. Hepatology 2007;45:507-539
8. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006;4:936-962
9. Tyzeka [prescribing information]. Cambridge, MA: Idenix Pharmaceuticals Incorporated, and East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2006
10. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-536
11. Wilber R, Brett-Smith H, Zhu J, et al, and the Entecavir Viral Kinetics Group 1. Entecavir (ETV) vs. adefovir (ADV): HBV DNA reduction in chronically infected HBeAg(+) nucleoside-naive adults in a 12-week viral kinetics study. Presented at: NIH Management of Hepatitis B Conference; April 6-8, 2006; Bethesda, MD. Poster 014
12. Chan HL-Y, Lai C-L, Cho M, et al. A randomized trial of telbivudine (LdT) vs. adefovir for HBeAg-positive chronic hepatitis B: results of the primary week 24 analysis. Presented at: 41st Meeting of the European Association for the Study of the Liver; April 26-30, 2006; Vienna, Austria.
13. Nafa S, Ahmed S, Tavan D, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32:1078-1088
14. Balzarini J, Wedgwood O, Kruining J, et al. Anti-HIV and anti-HBV activity and resistance profile of 2′,3′-dideoxy-3′- thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun 1996;225:363-369
15. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-1532
16. Guan R, Lai CL, Liaw YF, et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2001;16 (suppl 1):A60
17. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-696
18. Liaw YF. The current management of HBV drug resistance. J Clin Virol 2005;34(suppl 1):S143-S146
19. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-851
20. Liaw YF. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol 2002;17(suppl 3):S333-S337
21. Lo CM, Liu CL, Chan SC, et al. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005;43:283-287
22. Torresi J, Earnest-Silveira L, Deliyannis G, et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 2002;293:305-313
23. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-1751
24. Hepsera [prescribing information]. Foster City, CA: Gilead Sciences Inc; 2006
25. Colonno R, Rose R, Levine S, et al. Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients. Hepatology 2005;42(suppl 1):573A. Abstract 962
26. Borroto-Esoda K, Arterburn S, Snow A, et al. Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in HBeAg-negative patients. Presented at: Digestive Disease Week; May 21-24, 2006; Los Angeles, CA
27. Colonno R, Rose R, Pokornowski K, et al. Four year assessment of entecavir resistance in nucleoside naive and lamivudine refractory patients. Presented at: 42nd Annual Meeting of the European Association for the Study of Liver Disease; April 11-15, 2007; Barcelona, Spain
28. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006;44:1656-1665
29. DiBisceglie A, Lai C, Gane E, et al. Telbivudine GLOBE Trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Presented at: 57th Annual Meeting of the American Association for the Study of Liver Diseases; October 27-31, 2006; Boston, MA: Abstract 112
30. Lai CL, Gane E, Hsu C-W, et al. Two-year results from the GLOBE Trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine. Presented at: 57th Annual Meeting of the American Association for the Study of Liver Diseases; October 27-31, 2006; Boston, MA: Abstract 91
31. Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy. Gut 2005;54:1604-1609
32. Perrillo RP. Therapy of hepatitis B: viral suppression or eradication? Hepatology 2006;43(suppl 1):S182-S193
33. Cooksley G, Manns M, Lau GK, et al. Effect of genotype and other baseline factors on response to PEGInterferon α-2a (40kDa) (Pegasys®) in HBeAg-positive chronic hepatitis B: results from a large, randomized study. J Hepatol 2005;42(suppl 2):30-31. Abstract 71
34. Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006;101:297-303
35. Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006;44:1110-1116
36. van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006;44:318-325
37. Lim SG, Ng TM, Kung N, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006;166:49-56
38. Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003;39:1085-1089
39. Yang H, Westland C, Delaney WIV, et al. Complete genotypic and phenotypic analyses of HBV mutations identified in HBeAg-negative chronic hepatitis B patients receiving 96 weeks of adefovir dipivoxil (ADV). Hepatology 2003;38(suppl 1):705A. Abstract 1141
40. Standring DN, Seifer M, Patty A, et al. HBV resistance determination from the telbivudine GLOBE registration trial. Presented at: 41st Meeting of the European Association for the Study of Liver Diseases; April 26-30, 2006; Vienna, Austria. Poster 514
41. Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101
42. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90
43. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129
44. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-1217
45. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-2695
46. Yang H, Qi X, Sabogal A, et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005;10:625-633
47. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498-3507
48. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-2049
49. Van Bommel F, Mauss S, Zollner B, et al. Long-term effect of tenofovir in the treatment of lamivudine-resistant hepatitis B virus infections in comparison to adefovir. Hepatology 2005;42:269A. Abstract 184
50. Lampertico P, Vigano M, Iavarone M, et al. Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years. Hepatology 2006;44(suppl 1):556A. Abstract 989
51. Lampertico P, Marzano A, Levrero M, et al. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. Hepatology 2006;44(suppl 1):693A. Abstract LB5
52. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531
53. Fung SK, Andreone P, Han SH, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005;43:937-943
54. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263
55. Zoulim F, Poynard T, Degos F, et al. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat 2006;13:278-288
56. Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-791
57. Heo J, Cho M, Cho MB, et al. Predictors of lamivudine resistance in patients with chronic hepatitis B infection. Korean J Hepatol 2007;13:157-165